EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia



Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia



Oncotargets and Therapy 2: 219-228



Nelarabine is the prodrug of 9-beta-arabinofuranosylguanine (ara-G) and is therapeutically classified as a purine nucleoside analog. Nelarabine is converted to ara-G by adenosine deaminase and transported into cells by a nucleoside transporter. Ara-G is subsequently phosphorylated to ara-G triphosphate (ara-GTP), thereby initiating the therapeutic effect by inhibiting DNA synthesis. Nelarabine has been extensively studied in regards to its pharmacokinetics, and the data have demonstrated that ara-GTP preferentially accumulates in malignant T-cells. Clinical responses to nelarabine have been demonstrated in various T-cell malignancies and appear to correlate with a relatively high intracellular concentration of ara-GTP compared to nonresponders. Therefore, this unique drug feature of nelarabine accounts for clinical utilization in treating adult and pediatric patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Neuropathy is the most predominant adverse effect associated with nelarabine and the incidence correlates with the dose administered. Myelosuppression has been observed, with thrombocytopenia and neutropenia as the most common hematologic complications. This article reviews the pharmacology, mechanism of action, and pharmacokinetic properties of nelarabine, as well as nelarabine's clinical efficacy in T-ALL, T-LBL, and other hematologic malignancies. The toxicity profile, dosage, and administration, and areas of ongoing and future research, are also presented.

(PDF 0-2 workdays service: $29.90)

Accession: 055205606

Download citation: RISBibTeXText

PMID: 20616909



Related references

Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematology/Oncology Clinics of North America 23(5): 1121-35, Vii-Viii, 2010

Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Therapeutics and Clinical Risk Management 3(6): 1135-1141, 2008

Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. American Journal of Hematology 85(8): 608-608, 2010

Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Review of Hematology (): 1-8, 2016

Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia. American Journal of Hematology 88(12): 1096-1097, 2014

Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia. Medical Letter on Drugs and Therapeutics 48(1228): 14-15, 2006

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 109(12): 5136-5142, 2007

Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clinical Cancer Research 12(18): 5329-5335, 2006

Nelarabine for T-cell Acute Lymphoblastic Leukemia relapsing after allogeneic Hematopoietic Stem Cell Transplantation an opportunity to improve survival. 2013

Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. Biology of Blood and Marrow Transplantation 19(7): 1124-1126, 2014

Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease. Leukemia & Lymphoma 57(4): 957-960, 2015

FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist 13(6): 709-714, 2008

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. Journal of Hematology & Oncology 9(1): 114-114, 2016

Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Journal of Clinical Oncology 30(22): 2753-2759, 2012

Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatric Blood & Cancer 62(7): 1176-1183, 2015